Lumen Specialty Pharmacy On track
Specialty pharmacy · Minority equity · $19.5M deployed · Last report Oct 5
Performance
Last 12 months’ revenue, monthly.
$94.0M
+4.0% vs budget
(Revenue − cost of goods) ÷ revenue, last 12 months. New, added by Your Cohort
22.5%
+0.4 pts vs budget
Last 12 months’ EBITDA after approved adjustments, monthly.
$11.4M
+5.2% vs budget
Adj. EBITDA ÷ revenue.
12.1%
Budget 12.0%
Results vs budget and last year
As of Sep 30 · monthly
| Last 12 months | Actual | Budget | vs budget | Last year |
|---|---|---|---|---|
| Revenue | $94.0M | $90.4M | +4.0% | $86.2M |
| Gross margin | 22.5% | 22.1% | +0.4 pts | 21.9% |
| Operating costs | $9.7M | $9.8M | −0.4% | $9.9M |
| Adj. EBITDA | $11.4M | $10.8M | +5.2% | $10.3M |
From reported to adjusted EBITDA
What was added back, and why
Last 12 months · $M
- Reported EBITDA$10.6M
- + Pharmacy build-out (one-time)$0.5M
- + Owner pay normalized to market$0.2M
- + Non-cash stock pay$0.1M
- Adjusted EBITDA$11.4M
Reported and adjustedAdded back
| Step | Amount | Running total |
|---|---|---|
| Reported EBITDA | $10.6M | $10.6M |
| Pharmacy build-out (one-time) | +$0.5M | $11.1M |
| Owner pay normalized to market | +$0.2M | $11.3M |
| Non-cash stock pay | +$0.1M | $11.4M |
| Adjusted EBITDA | $11.4M | $11.4M |
Adjustments are 7% of the total. The build-out costs stop after this year.
Turnaround plan
Not needed. The company is on plan; Your Cohort reviews it monthly.
New marks a measure Your Cohort adds to Thorne’s reporting · fictional companies and figures · thresholds are placeholders · select or hover any dotted label for its definition